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Abstract 
 
Amyloid plaques consisting of aggregated Aß peptide are a hallmark of 
Alzheimer’s disease (AD), the most common form of neurodegenerative disease. 
Among the different forms of Aß, the one of 42aa length (Aß42) is the most 
aggregation prone and also the most neurotoxic, whereby oligomers of this peptide, 
rather than large aggregates, are considered to be most damaging. Expression of 
Aß42 in transgenic Drosophila under the control of an eye-specific 
enhancer/promoter (GMR) results in a degeneration of eye structures that 
progresses with age. We find that dietary supplement of zinc or copper ions 
exacerbates eye damage, while supplementing food with zinc/copper chelators 
ameliorates the pathological phenotypes. Positive effects are also seen upon 
overexpression of MTF-1, a conserved transcription factor for cell stress response, 
especially heavy metal stress and oxidative stress, or with transgenes encoding 
metallothioneins, cysteine-rich metal scavenger proteins (human MT3 or 
Drosophila MtnA). Aß42-mediated damage likely involves oxidative stress, 
because overexpression of GCL, the key enzyme of glutathione synthesis, also 
ameliorates toxicity. These results show that a tight control of zinc and copper 
availability can minimize cellular damage associated with Aß42 induced oxidative 
stress.  
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Introduction  
 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by 
amyloid plaques and neurofibrillary tangles in the brain (Goedert and Spillantini, 
2006). So far there is no cure and its molecular basis is only partially understood. 
The main component of amyloid plaques, amyloid ß peptide (Aß), is generated 
from ß-amyloid precursor protein (APP) by proteolytic cleavage (Kang et al., 
1987). Aß occurs in various lengths, due to the successive cleavage by the gamma-
secretase of the APP derived substrate C99 (Takami et al. 2009). Aß42 is the most 
aggregation-prone and also the most neurotoxic form. The monomeric form of Aß 
is not toxic (Selkoe, 2008) or at least less toxic than aggregated low-n multimers 
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(Harmeier et al., 2009; Kayed et al., 2003; Selkoe, 2008). Cell-free studies have 
revealed that binding of Cu(II) or Zn(II) strongly promotes the aggregation of 
synthetic Aß (Atwood et al., 1998; Bush et al., 1994). Also, metal chelators can 
dissolve the Aß plaques from postmortem AD brains (Cherny et al., 1999). 
Amyloid plaques are highly enriched for zinc, copper and iron ions (Lovell et al., 
1998). Studies have shown that histidine residues at positions 6, 13 and 14 are 
crucial for Aß to bind Zn(II) and Cu(II) (Atwood et al., 2000; Danielsson et al., 
2007). Aß-copper complexes were shown in vitro to generate reactive oxygen 
species (ROS) via a Fenton-like reaction (Huang et al., 1999). The fact that Aß42 
in this assay has a higher propensity to generate ROS than Aß40 could, at least in 
part, explain why Aß42 is more neurotoxic. However, AD patients were found to 
have decreased copper levels in the cortex (Cottrell et al., 2001; Maurer et al., 
2000) and in a mouse model of AD, copper supplementation reduced amyloid 
plaque formation and increased the activity of the antioxidant enzyme Cu/Zn SOD 
(Bayer et al., 2003). This somewhat counter-intuitive beneficial effect of copper 
prompted a one-year clinical study with copper supplementation to AD patients. 
This study did not yield conclusive results in terms of amelioration of cognitive 
performance but also had no negative effects (Kessler et al., 2008a; Kessler et al., 
2008b). To study the effect of Aß42 expression in the context of varying 
concentrations of metal ions, we used the fruit fly Drosophila as a model. Our data 
demonstrate that zinc, copper and oxidative stress enhance the toxicity of Aß42 
while metal chelators, metal scavengers, antioxidant proteins and especially the 
transcription factor MTF-1, a key regulator of heavy metal homeostasis in higher 
eukaryotes, attenuate Aß-mediated phenotypes. Taken together, antioxidant 
therapies and a tight control of trace metals may represent potential strategies for 
treating Alzheimer’s disease. 
 
 
 
 
Results 
 
Zinc and copper food supplements strongly enhance the toxicity of Aß42 
 
To investigate the toxicity of Aß42 in vivo, we generated transgenic flies 
expressing Aß42 peptides. Aß42 peptide expression levels and signal peptide 
processing in the transgenic flies were verified by Western blot and mass 
spectrometry (Fig 1). Aß42 expressed under the control of an eye-specific driver 
(GMR-Gal4) causes a range of abnormalities. The severity of the eye phenotype 
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correlates with the Aß42 expression level and the age of the flies, i.e., when the 
expression level is higher or the flies are older, eye malformations are more 
pronounced (Fig 2).  
 
To test the effect of zinc and copper ions on Aß42 toxicity, fly food was enriched 
for these essential metals. Based on previous experiments, 4 mM zinc or 500 M 
copper were chosen. Such treatments did consistently enhance the eye distortion 
phenotype (Fig 3C, D).  To find out whether the effect of zinc and copper on Aß42 
toxicity was indirect, or direct due to the binding of zinc and copper to the Aß42 
peptide, a copper/zinc binding site (His 6, 13 and 14) was mutated in Aß42. 
Expression of such a mutant form of Aß42 caused only a mild phenotype, which 
could not be enhanced by zinc supplement (Fig 3G, H). Expression of Aß42 under 
the control of a ubiquitous driver (actin-Gal4) decreased the survival rate of the 
flies (Fig 4A). Viability was further reduced by zinc supplement, but not by copper 
supplement or copper depletion, indicating that from the two metals, a body-wide 
surplus of zinc has more severe consequences. Consistent with a prominent role for 
zinc in Aß toxicity, DP-109, a zinc/copper chelator of the family of membrane-
activated chelators (MACs), enhanced the fraction of Aß42-expressing flies 
developing to adulthood (Fig 4A) (Kolusheva et al., 2005; Lee et al., 2004; Petri et 
al., 2007). Eye malformation caused by eye-specific Aß42 expression was however 
exacerbated by both zinc and copper supplement and reversed by both DP-109 and 
BCS administration (Fig 4B-E). The eye phenotypes of wild type flies were not 
affected by copper or zinc treatment (data not shown). When the expression of 
Aß42 was directed to the nerve system by using a neuron-specific driver (elav-
Gal4) the flies exhibited defects in locomotion which were exacerbated by zinc 
supplement, as measured by a standard climbing assay: the number of control flies 
able to climb the vertical distance within a given time fell from 100% at day 1 to 
93% at day 5 to 72% at day 10. By contrast, the number of successful flies on food 
with 4 mM zinc fell in the same time from 80% to 33% to 3%. Under these latter 
conditions, there was a strong rescue effect with MAC-type chelator DP-460 
supplement at 100  (Fig 4F).  
 
MTF-1 and metallothioneins inhibit Aß toxicity 
 
The zinc finger transcription factor MTF-1 (metal responsive transcription factor, 
or metal response element binding transcription factor), is a key regulator of heavy 
metal homeostasis and metal detoxification from insects to mammals (Egli et al., 
2003; Radtke et al., 1993; reviewed in Andrews, 2001; Balamurugan and 
Schaffner, 2006; Lichtlen and Schaffner, 2001; Rutherford and Bird, 2004). MTF-
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1 is also involved in the cellular defense against other stress conditions, including 
hypoxia and oxidative stress. While the lack of MTF-1 renders flies sensitive to 
metals, overexpression of MTF-1 confers enhanced protection against heavy metal 
stress (Balamurugan et al., 2007). In our model system, elevated expression of 
MTF-1 or of one of its major target genes, metallothionein A (MtnA), strongly 
ameliorated Aß toxicity (Fig 5C, D). Conversely, in an MTF-1 null mutant 
background, Aß exerted more severe damage to the eye tissue (Fig 5B). We also 
tested metallothionein 3 (MT3) in our Drosophila system because in humans, it is 
the most abundant metallothionein in the brain. A human MT3 transgene co-
expressed with Aß42 indeed suppresses Aß-mediated phenotypes (Fig 5E).  
  
Oxidative stress and Aß toxicity 
 
To investigate how oxidative stress affects Aß42 toxicity, we treated Aß42 
expressing flies with hydrogen peroxide. Our results reveal that, at a dosage that 
does not affect wild type flies, hydrogen peroxide strongly enhances the eye 
distortion phenotype in Aß42 transgenic flies (Fig 6D). Since oxidative stress 
increased Aß42 toxicity, we reasoned that antioxidant genes might counteract 
Aß42 toxicity. In support of this idea, transgenes encoding either one of the two 
subunits of Drosophila glutamate-cysteine ligase (GCL), the key enzyme for 
glutathione synthesis, was able to ameliorate Aß42 toxicity (Fig 6E, F).     
 
Aß induces apoptosis  
 
To shed more light on the mechanism of Aß42-induced cell death in our 
Drosophila model, we tested the effect of suppressing apoptosis in our transgenic 
flies. To this end we either crossed in a small chromosomal deletion (DfH99) or 
co-expressed p35 protein. DfH99 deletes three pro-apoptotic genes, namely hid, 
grim and reaper. In a homozygous state the deletion is lethal, but even in 
heterozygous flies programmed cell death is strongly reduced. p35 is a caspase-
inhibitory protein derived from baculovirus. Our results show that both the 
expression of p35 or the deletion DfH99 in heterozygous state decrease the level of 
cell death induced by Aß42 (Fig 7). The fact that eye structures were not fully 
rescued might mean that apoptosis was incomplete, or that other mechanism(s) 
such as necrosis also contributed to Aß42-induced cell death.  
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Discussion 
 
Aß peptides are widely regarded as the primary culprits in Alzheimer’s disease 
(Selkoe, 2001). There is compelling evidence that Aß exerts neurotoxicity (Gong et 
al., 2003; Harmeier et al., 2009; Hsieh et al., 2006; Selkoe, 2008; Shankar et al., 
2007; Simmons et al., 1994); however, it is not fully understood what factors affect 
Aß toxicity in a living organism. In recent years, Drosophila models for 
Alzheimer’s disease were developed (Finelli et al., 2004; Greeve et al., 2004; 
Crowther et al., 2005). Work from these groups has shown that Drosophila 
recapitulates several pathological features also seen in human AD. Based on this 
knowledge we generated a Drosophila model for AD to test various genetic and 
environmental factors that might affect the toxicity of Aß42. Several factors (such 
as insulin-degrading enzyme, apolipoprotein E, oxidative stress) which have been 
shown to be related to Alzheimer’s disease were studied in Drosophila models 
(Rival et al., 2009; Sarantseva et al., 2009; Sofola et al., 2010; Tsuda et al., 2010). 
These studies further support the notion that Drosophila models do reflect some 
key molecular pathological features of Alzheimer’s disease. 
 
For the experiments presented here we generated Drosophila strains expressing 
secreted A42 and tested various genetic and environmental factors that might 
affect the toxicity of Aß42. We demonstrate that elevated zinc (and copper) levels 
enhance Aß toxicity. By contrast, in an Aß mutant that lacks the metal binding site, 
eye damage is generally less severe and cannot be exacerbated by zinc 
supplementation. One might argue that the milder phenotype caused by this mutant 
Aß42 was merely due to a lower expression level. However, we consider this 
unlikely for two reasons: first, thanks to site-specific integration, both wild type 
and mutant(s) were inserted at the same chromosomal locus and driven by the 
same promoter, which eliminates chromosomal position effects. Second, the 
phenotype of the mutant was unaffected by zinc supplement, which also argues for 
a specific and direct metal effect on Aß42.   
 
A previous study has revealed that chelation of copper reduces Aß-mediated 
hydrogen peroxide generation and oxidative damage (Huang et al., 1999). 
However, the influence of copper levels on AD might well be more complex than 
what we have found in our Drosophila model where elevated copper availability 
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enhances the toxicity of Aß. Copper also binds to APP and BACE and modulates 
APP processing and Aß peptide production (Angeletti et al., 2005; Barnham et al., 
2003; Simons et al., 2002). Overexpression of APP caused decreased intracellular 
Cu levels in the brain of transgenic mice (Maynard et al., 2002). In the brains of 
AD patients, copper homeostasis is disturbed, whereby copper is enriched in the 
amyloid plaques but its overall level is decreased, resulting in a reduced Cu/Zn 
SOD-1 activity (Lovell et al., 1998). In a transgenic mouse model of AD, dietary 
Cu restored the function of SOD-1 and reduced plaque formation (Bayer et al., 
2003). In a recent phase II clinic trial in patients with mild AD, oral intake of 8 mg 
Cu/day had neither a positive nor a negative effect (Kessler et al., 2008a; Kessler et 
al., 2008b).  Further studies will have to be carried out to elucidate the effect of 
copper on the molecular level, i.e. on Cu-binding proteins that represent key 
molecules in AD.  
 
Recently, metal chelators were developed as a putative treatment for AD. Among 
them, clioquinol (CQ) was shown to decrease Aß deposition in Tg2576 transgenic 
mice (Cherny et al., 2001) and in a phase II clinical trial was found to have 
beneficial effects. A phase III clinical trial termed PBT2, see 
http://www.alzforum.org/drg/drc/detail.asp?id=110 is under way. We have tested 
metal chelators, notably DP-109 and DP-460 from the MAC (“membrane activated 
chelator”) family. By attaching to the cell membrane, MACs avoid the problems 
that could be caused by a general chelation of metals, and they were shown to be 
neuroprotective in transgenic mouse models (Kolusheva et al., 2005; Lee et al., 
2004; Petri et al., 2007). These and our results indicate that MACs can efficiently 
counteract the deleterious effects of metals in conjunction with Aß. Of note, upon 
systemic expression of Aß42, DP-109 was active in the survival assay wheras the 
copper-specific chelator BCS had little effect. This suggests that DP109’s major 
effect under this condition was the chelation of zinc. We also observed that MAC 
treatment does not interfere with the uptake of zinc and copper in flies (data not 
shown). However, chelators may be beneficial by other means. For example, since 
AD patients tend to have a copper deficiency in their brain it was suggested that 
the above-mentioned clioquinol functions as a copper carrier to effectively increase 
intracellular copper levels (Treiber et al., 2004). Whatever the mechanism, 
concentrations of extracellular and intracellular/bioavailable metals may critically 
influence the time of onset and the progression of AD. 
 
In addition to metal chelators, we found that expression of the key regulator of 
metal homeostasis, MTF-1, or of human or Drosophila metallothioneins is also 
capable of reducing Aß phenotypes. Although it is still unclear whether reduced 
levels of metallothioneins, notably of the brain-enriched MT-3/GIF, contribute to 
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AD (Erickson et al., 1994; Uchida, 1994; Uchida et al., 1991), our results are 
consistent with earlier findings that metallothioneins have neuroprotective 
functions (Irie and Keung, 2003; Meloni et al., 2008; Penkowa, 2006; West et al., 
2008). We have previously shown that flies lacking Parkin, an ubiquitin ligase 
involved in Parkinson’s disease, also benefit from a tight control of copper 
availiability and upregulation of antioxidant response (Saini et al., 2010). In line 
with the findings presented here, elevated expression of MTF-1 dramatically 
improved the condition of the parkin mutant (Saini et al., 2011). However, unlike 
the Aß transgenics where extra zinc is at least as bad, if not worse than copper, 
zinc supplementation has a strong beneficial effect on the parkin mutant (Saini and 
Schaffner, 2010). Taken together, these findings underline the importance of 
metals as modulators in pathogenic processes, notably ones that are related to 
human neurodegenerative diseases, but they also indicate specific requirements 
depending on the condition.  
 
A large body of evidence indicates that oxidative stress contributes to AD. AD 
patients have higher concentrations of oxidative stress markers than age-matched 
controls (Markesbery and Lovell, 1998). In line with this concept, there is evidence 
that Aß generates reactive oxygen species (ROS), especially hydrogen peroxide 
and hydroxyl radical, when bound to redox-active metals (Huang et al., 1999). 
More recently, this was explored in a Drosophila model where catalase and the 
iron-binding protein ferritin were able to suppress the toxic effect of Aß (Rival et 
al., 2009). The latter is intriguing in light of the fact that ferritin gene expression is 
induced via MTF-1 (Yepiskoposyan et al., 2006). In our model system, increased 
levels of oxidative stress correlate with more severe Aß-induced phenotypes. We 
also found that overexpression of glutamate-cysteine ligase (GCL), an essential 
protein complex for glutathione production, is able to reduce Aß mediated cell 
death. Taken together, the toxicity of Aß peptides can be reduced either by 
chelation of aggregation-promoting or redox-active metal ions (Zn, Cu, Fe), or by 
reducing oxidative stress. Since MTF-1 is involved in the defense against several 
cell stress conditions and is effective in Drosophila models of Parkinson’s and 
Alzheimer diseases (Saini et al., 2011 and shown here), polymorphisms in MTF-1 
gene expression might modulate the course of AD and other human 
neurodegenerative diseases. 
 
Alzheimer’s disease is a complex multifactorial disorder. Further investigations on 
metal-ion mediated effects, such as those described here, will shed light on the 
molecular mechanisms involved. This knowledge might serve as a basis for 
developing novel genetic or pharmacological therapies to prevent, or at least 
ameliorate, AD pathogenesis.  
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Materials and methods 
 
Fly culture 
 
1 liter of standard fly food was composed of 55 g corn, 10 g wheat, 100 g yeast, 75 
g glucose, 8 g agar, and 15 ml anti-fungal agent nipagin (15% in ethanol, m/v). For 
experiments, food was supplemented to the indicated concentrations with either 
CuSO4, ZnCl2, the copper chelator bathocuproinedisulfonate (BCS) disodium salt 
hydrate (Sigma-Aldrich No. 14,662-5) or “membrane activated chelators” DP-109 
and DP-460 (D-Pharm, Rehovot) to the indicated concentrations. For simplicity, 
the ionic metal compounds are in most cases referred to as zinc (Zn) or copper 
(Cu). Flies were raised at 25ºC and 65% humidity.  
 
Plasmids and fly transformation 
 
The Aß42 coding sequence with the signal peptide sequence of the Drosophila 
hedgehog protein was cloned into the P element transformation vector pUAST. 
The sequence of Aß42 with the signal peptide is: 
mdnhssvpwasaasvtclsldakchssssssssksaassisaipqeetqtmrhiahtqrclsrltslvalllivlpmvfs
pahsDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA, 
whereby lower case and capital letters denote signal peptide and Aß42 sequences, 
respectively). To achieve expression of human brain-enriched metallothionein 
(MT3) in Drosophila, the coding sequence of MT3 (a gift from Milan Vasak) was 
cloned into the pUAST vector. Flies were transformed by standard P element 
transposition. The resulting transgenic fly strains that were used in this work were 
termed UAS-Aß42-high, UAS-Aß42-medium, and UAS-hMT3. Transgenic flies 
that express Aß42 without signal peptide were generated in the same manner and 
the resulting fly strain was termed UAS-Aß42-no-SP. The phage C31 site-specific 
integration system was used to introduce sequences coding for Aß42, or mutant 
Aß42 where three histidines (His 6, 13 and 14 of the metal binding site) were 
changed into arginines. Wild type and mutant Aß42 segments were cloned into a 
pattB vector containing the 5XUAS enhancer/promoter and introduced into flies 
via an AttP landing site (line ZH-86Fb). The resulting transgenic flies are 
designated UAS-Aß-attB and UAS-Aß-3HR-attB. To direct Aß42 expression to 
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the nerve system, the Gal4 driver was expressed from the elav enhancer/promoter 
(the elav-Gal4 strain was obtained from the Bloomington Stock Center). 
 
Fly stocks 
The deficiency DfH99 and the UAS-p35 fly strains were kind gifts from Konrad 
Basler and Peter Gallant (University of Zurich), respectively. The UAS-GCLc and 
GCLm flies were a gift from William C. Orr (Southern Methodist University, 
Dallas, Texas). 
 
Western blot and mass spectrometry 
 
Protein was isolated from control flies and Aß42 expressing flies with RIPA buffer 
(50 mM Tris-HCl/ 0.5% sodium deoxycholate/ 1% NP-40/150 mM sodium cloride/ 
1% SDS). G-Sepharose beads were preincubated with AWO-2 antibody against Aß 
before being used for immunoprecipitation of Aß peptides from the protein lysate. 
After immoprecipitation, samples were loaded on a Novex 10%-20% Tricine 
gradient gel. For Maldi-MS, after immunoprecipitation, samples were washed 
twice with PBS and then washed twice with 50% ammonium acetate. Elution was 
done with 25% ammonium hydroxide. Maldi-MS was performed as previously 
described.  
 
Eye section 
 
Unless specified otherwise, adult flies were collected at 5 days of age and eye 
sections were analyzed with a Leica Leitz DMRB fluorescence stereomicroscope 
as previously described. Images were taken with a Zeiss Axiocam. There were 
some minor structural variations depending on the plane of section; however, a 
distorted eye structure was always evident irrespective of the plane of section.  
 
Survival assay 
 
The survival index was calculated based on the eclosure rate of the flies (i.e., flies 
completing development to adulthood). Flies that carry a UAS-Aß42S7 transgene 
were crossed with actin-Gal4/TM3,y+ flies on standard food or on food containing 
either Cu, Zn, DP-109 or BCS. From the cross, two types of progeny could be 
obtained: (A) flies that were expressing Aß42 or (B) control flies that did not 
express Aß42. The survival index (i.e. relative eclosure rate) was calculated as 
2A/(A+B). 
 11 
 
Locomotion assay 
 
Locomotor activity was measured with a negative geotaxis assay. Groups of 
female flies were transferred into empty 95 x 27 mm glass tubes which were 
marked with a horizontal line 7.5 cm above the bottom. Flies were gently shaken 
down to the bottom of the vial and after 10 s the number of flies that had climbed 
beyond the 7.5 cm mark was recorded. All the studies were performed under 
standardized light conditions. 
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Fig 1. Expression of Aß42 in Drosophila 
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A) Western blot with Aß-specific antibody (WO-2) to detect Aß42 in transgenic 
fly strains. Aß42 peptides extracted from various transgenic flies expressing Aß42 
(Aß42-medium and Aß42-high). The N-terminal signal peptide is correctly 
processed because it runs at the same position as the one from flies expressing 
Aß42 without signal peptide from transgenic line Aß42-no-SP and the synthetic 
Aß42 as positive control (arrow). B) Protein extract from UAS-Aß42-high/+; 
GMR-Gal4/+ flies analyzed by mass spectrometry. In accordance with the Western 
blot in A), the molecular weight of the peak peptide corresponds to Aß42 without 
signal peptide. 
 
Fig 2. Aß42 expression in the eye causes progressive eye degeneration 
correlated with age and expression levels 
While the solid surface of the complex eyes remained largely intact, sections 
revealed a progressive decay of ommatidial organization in Aß42-expressing vs. 
control flies: controls expressing only the GMR-Gal4 driver maintained normal 
structures either in young (1-day) (A) and old (30-day) flies (B). Aß-dependent eye 
degeneration was more severe in 30-day-old flies (D) than in 1-day-old flies (C).  
(E) and (F) show eye sections of 5-day-old flies expressing Aß42 either moderately 
(UAS-Aß-medium/+; GMR-Gal4/+), or at high level (UAS-Aß-high/+; GMR-
Gal4/+). Note that complex eyes were not always cut at the very same level, hence 
even the contours of intact ommatidia may show some variation in this and the 
following figures; nevertheless, a distorted ommatidial structure was always 
evident irrespective of the plane of section. 
 
Fig 3. Zinc or copper food supplement exacerbates eye distortion 
Eye sections are shown of adult flies that had been kept in different food for 5 days 
after eclosure from the puparium. These include control flies (GMR-Gal4/+) grown 
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on standard food (NF) (A) or flies expressing Aß42 in the eyes (UAS-AßS3/+; 
GMR-Gal4/+), also grown on standard food (B) or on food with 4 mM Zn (C) or 
500 M Cu (D). Flies expressing Aß42 (E, F) or mutant Aß42 with 3His->Arg 
substitutions to abolish metal binding (G, H) were grown on either standard food 
(NF) (E, G) or food containing 4 mM Zn (F, H).  
 
 
Fig 4. Metal chelaters ameliorate Aß42-mediated phenotypes 
(A) Survival assay using control flies and Aß42 expressing flies. Ubiquitous 
expression of Aß42 via actin-Gal4 reduced viability, as evident by a lower eclosure 
rate (flies completing development to adulthood). The decline in survival was 
counteracted by supplementation with the Zn/Cu chelator DP-109 but not by 
supplementation with BCS chelator which preferentially binds Cu(I). (B)-(E) Eye 
sections of 5-day-old UAS-Aß42-medium/+; GMR-Gal4/+ flies raised on food 
containing 500 M Cu (B) or 4 mM Zn (C); on food containing both 500 M Cu 
and 250 M BCS (D), or both 4 mM Zn and 100 M DP-109 (E). (F) A climbing 
assay (cf. Materials and Methods) was used to monitor the effect of Aß42 
expression in the nerve system. UAS-Aß42-high/elav-Gal4 flies were raised and 
kept on standard food (NF), or food containing 4 mM Zn or food containing 4 mM 
Zn in combination with DP-460 (100 M). 
 
Fig 5. MTF-1 and metallothioneins ameliorate Aß42-mediated eye 
degeneration 
Shown are eye section pictures of  5 day-old flies expressing Aß42 alone (A) or 
flies co-expressing Aß42 and the key transcription factor for heavy metal 
homeostasis and detoxification, Drosophila MTF-1 (C), the major Drosophila 
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metallothionein MtnA (D), or human brain-specific metallothionein MT3 (E). (B) 
Eye phenotype of Aß42 expression in flies lacking the metal responsive regulator 
MTF-1. 
 
Fig 6. Aß42-expressing flies, but not control flies, are hypersensitive to 
hydrogen peroxide 
The eyes of control flies (GMR-Gal4/+) displayed no obvious difference between 
standard food (A) and food containing 0.025% H2O2 (B). However, flies 
expressing Aß42 treated with 0.025% H2O2 (D) showed stronger eye degeneration 
than those grown on standard food (C).  By contrast, transgenes encoding catalytic 
(GCLc) and modifier (GCLm) subunits of glutamate-cysteine ligase, a key enzyme 
for glutathione synthesis had beneficial effects in Aß42 expressing flies (E, F).  
 
Fig 7. Aß42 induces cell death mainly via apoptosis 
The extent of cell death in an eye that expresses Aß42 alone (A) was reduced when 
Aß42 was expressed on the background of a genomic deletion (DfH99) that 
removes the pro-apoptotic genes reaper, grim and hid (B), or upon co-expression 
of the viral anti-apoptotic protein p35 (C).  
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